Head of Pediatric Follow-up Group at University of Bergen and the Pediatric Clinical Trials Unit at Haukeland University Hospital.

Her research is especially focused on nephrology, immunology and clinical trials. As part of NorCRIN (since 2012) and NorPedMed (since 2014) she works for more clinical trials in Norway. She is ECRINs Norwegian scientific representative, leader of the Norwegian Pediatric Nephrology Group in Norwegian Society of Pediatrics and national ESPN-representative.

Head of Teaching, Department of Clinical Science, University of Bergen  

MED9: Pediatric nephrology and rheumatology. Paediatric Pharmacology. General Pediatrics. Paediatric Fluid Therapy. Intoxications. Social Pediatrics.

MED5: Communication with children and adolescents

GCP901: Course leader. Course in clinical studies including ICH-GCP

MEDMET1: ICH-Good Clinical Practice

NUCLI352: Pediatric Nephrology

Academic article

• Holida, Myrl; Linhart, Aleš; Longo, Nicola et al. (2026). Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. (external link)
• Camilla Tøndel; Synne Jenum; Kristian Tonby et al. (2026). SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. (external link)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2009). Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. (external link)
• Rannveig Skrunes; Einar Svarstad; Kristin Kampevold Larsen et al. (2016). Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. (external link)
• Antonio C Arrieta; Jocelyn Y Ang; Claudia Espinosa et al. (2021). Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. (external link)
• Lena Hansen; Karl Albert Brokstad; Amit Bansal et al. (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. (external link)
• Frits Wijburg; Bernard Benichou; Daniel G Bichet et al. (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. (external link)
• Camilla Tøndel; Takahiro Kanai; Kristin Kampevold Larsen et al. (2015). Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. (external link)
• Camilla Tøndel; Leif Bostad; Kristin Kampevold Larsen et al. (2013). Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. (external link)
• Giacomo Casabona; Ahsan Habib; Michael Povey et al. (2021). Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. (external link)
• John S Bradley; Nataliia Makieieva; Camilla Tøndel et al. (2023). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. (external link)
• Nina Urke Ertesvåg; Julie Xiao; Fan Zhou et al. (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. (external link)
• Bjørn Steinar Lillås; Camilla Tøndel; Anna Gjerde et al. (2019). Measurement of renal functional response using iohexol clearance-A study of different outpatient procedures. (external link)
• Camilla Tøndel; Hans Peter Marti (2021). Cardiovascular changes in young renal failure patients. (external link)
• Julian F Guest; Trond Jenssen; Gunnar Houge et al. (2010). Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. (external link)
• Einar Svarstad; Sabine Maria Leh; Rannveig Skrunes et al. (2017). Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. (external link)
• Øystein Solberg Eikrem; Rannveig Skrunes; Camilla Tøndel et al. (2017). Pathomechanisms of renal Fabry disease. (external link)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2010). Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. (external link)
• Heidi Syre; Marius Eduardo Brå Obreque; Ingvild Dalen et al. (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. (external link)
• Sanne van der Veen; Simon Körver; A Hirsch et al. (2021). Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. (external link)
• Eric Wallace; Ozlem Goker-Alpan; William R Wilcox et al. (2023). Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: Results from the 2-year randomised phase III BALANCE study. (external link)
• Gabor E. Linthorst; Allessandro Burlina; Franco Cecchi et al. (2012). Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. (external link)
• Camilla Tøndel; Bjørn Egil Vikse; Leif Bostad et al. (2012). Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. (external link)
• Hassan Osman Alhassan Elsaid; Mariell Lossius Rivedal; Eleni Skandalou et al. (2023). Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla ^−/− zebrafish model of Fabry disease. (external link)
• Kristin M. Aakre; Camilla Tøndel; Atle Brun et al. (2009). The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. (external link)
• Nicolas Delaleu; Hans Peter Marti; Philipp Strauss et al. (2023). Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. (external link)
• Aleš Linhart; Gabriela Dostalova; Kathy Nicholls et al. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. (external link)
• Linda van der Tol; David Cassiman; Gunnar Houge et al. (2014). Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. (external link)
• Geir Bredholt; Marianne Sævik; Hanne Søyland et al. (2024). Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. (external link)
• Mai Chi Trieu; Amit Bansal; Anders Madsen et al. (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (external link)
• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2016). Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2020). Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. (external link)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2015). Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. (external link)
• Hassan Osman Alhassan Elsaid; Jessica Furriol; Maria Blomqvist et al. (2022). Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. (external link)
• Thea Tislevoll Eide; Karl Ove Hufthammer; Atle Brun et al. (2021). Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. (external link)
• Bjørn Steinar Lillås; Camilla Tøndel; Jörg Assmus et al. (2021). Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. (external link)
• Eefje B. Suntjens; Wouter Albert Dreschler; Jeanette Hess-Erga et al. (2017). Hearing loss in children with Fabry disease. (external link)
• Elisabeth Berg Fjelltveit; Bjørn Blomberg; Kanika Kuwelker et al. (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. (external link)
• Fabian Braun; Ahmed Abed; Dominik Sellung et al. (2023). Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. (external link)
• Einar Svarstad; Leif Bostad; Øyvind Kaarbøe et al. (2005). Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. (external link)
• Michael Mauer; Emily Glynn; Einar Svarstad et al. (2014). Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. (external link)
• Camilla Tøndel; Liv Marie Lægreid; Asle Hirth et al. (2003). [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease]. (external link)
• Linda van der Tol; Einar Svarstad; Alberto Ortiz et al. (2014). Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. (external link)
• Cathrin Lytomt Salvador; Per Trygge Kjelland Flemmen; Camilla Tøndel et al. (2023). Renal function, sex and age influence purines and pyrimidines in urine and could lead to diagnostic misinterpretation. (external link)
• Cathrin Lytomt Salvador; Camilla Tøndel; Alexander D. Rowe et al. (2017). Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. (external link)
• Amit Bansal; Mai Chi Trieu; Kristin Greve-Isdahl Mohn et al. (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. (external link)
• Petur Benedikt Juliusson; Camilla Tøndel; Sylvi Aanderud et al. (2002). Behandling av Graves sykdom hos barn og unge. (external link)
• Hassan Osman Alhassan Elsaid; Håkon Tjeldnes; Mariell Lossius Rivedal et al. (2022). Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca²⁺ Signaling Similar to Fabry Disease. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2016). One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. (external link)
• Camilla Tøndel; Leif Bostad; Asle Hirth et al. (2008). Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. (external link)
• Alessandro Burlina; Thomas Duning; Julian Fernandez-Martin et al. (2024). Fabry disease: current gaps and actionable solutions to improve Fabry patients’ clinical journey. (external link)
• Myrl Holida; Aleš Linhart; Antonio Pisani et al. (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (external link)
• Ann Christin Gjerstad; Rannveig Skrunes; Camilla Tøndel et al. (2022). Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up. (external link)
• David Moreno-Martinez; Patricio Aguiar; Christiane Auray-Blais et al. (2021). Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. (external link)
• Kristin Greve Isdahl Mohn; Karl Albert Brokstad; Shahinul Islam et al. (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. (external link)
• Kanika Kuwelker; Fan Zhou; Bjørn Blomberg et al. (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. (external link)
• Małgorzata Baka‐Ostrowska; David T. Bolong; Cristian Persu et al. (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. (external link)
• Fan Zhou; Juha Vahokoski; Siri Øyen et al. (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. (external link)
• Kristin Greve Isdahl Mohn; Karl Albert Brokstad; Rishi Pathirana et al. (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. (external link)
• Daniel G Bichet; Robert J. Hopkin; Patricio Aguiar et al. (2023). Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. (external link)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Toralf Melsom et al. (2023). Renal Functional Response-Association With Birth Weight and Kidney Volume. (external link)
• Hjørdis Thorsteinsdottir; Cathrin Lytomt Salvador; Geir Mjøen et al. (2020). Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. (external link)
• Robert J. Hopkin; Ana Martins; Julia Alton et al. (2024). Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years. (external link)
• Robert J. Hopkin; Gustavo Cabrera; John Jefferies et al. (2022). Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry registry. (external link)
• Kristin Greve Isdahl Mohn; Geir Bredholt; Karl Albert Brokstad et al. (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. (external link)
• Bjørn Blomberg; Kristin Greve-Isdahl Mohn; Karl Albert Brokstad et al. (2021). Long COVID in a prospective cohort of home-isolated patients. (external link)
• David Smerkous; Michael Mauer; Camilla Tøndel et al. (2023). Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.. (external link)
• Christiane Lerche Sandbye; Rukshana Shroff; Mandy Wan et al. (2018). Effects of nutritional Vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. (external link)
• Rannveig Skrunes; Camilla Tøndel; Sabine Maria Leh et al. (2017). Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. (external link)
• Marieke Biegstraaten; R Arngrímsson; F Barbey et al. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. (external link)
• Cathrin Lytomt Salvador; Camilla Tøndel; Alexander D. Rowe et al. (2018). Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. (external link)
• Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy et al. (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. (external link)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2017). Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. (external link)
• Behzad Najafian; Einar Svarstad; Leif Bostad et al. (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. (external link)
• Uma Ramaswami; Daniel G Bichet; Lorne Clarke et al. (2019). Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. (external link)
• Marco Spada; Ralf Baron; Perry M. Elliott et al. (2018). The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. (external link)
• Søren Rittig; Malgorzata Baka-Ostrowska; Camilla Tøndel et al. (2019). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. (external link)
• Nori JL Smeets; Esther MM Teunissen; Kim van der Velden et al. (2022). Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. (external link)

Media interview

• Camilla Tøndel (2025). Vil ha tidlig pottetrening: – Vi lærer ungene å tisse på seg. (external link)
• Camilla Tøndel (2022). Nye behandlingsformer for Fabrys sykdom under utprøving. (external link)
• Camilla Tøndel; Are Stuwitz Berg (2024). Vaksine mot vannkopper. (external link)
• Camilla Tøndel (2024). Foreslår at alle barn skal få vaksine mot vannkopper fra neste år. (external link)
• Camilla Tøndel (2021). Her settes første dose av norskutviklet koronavaksine. (external link)
• Rebecca Jane Cox; Camilla Tøndel; Anne Spurkland et al. (2023). Bør alle norske barn vaksineres mot vannkopper?. (external link)
• Camilla Tøndel (2013). Forskning på medisiner til barn, Ekko. (external link)
• Camilla Tøndel (2024). Evolving screening and diagnosis strategies in Fabry disease. (external link)
• Maria Winther Gunnes; Camilla Tøndel (2014). Kampen mot kreft. (external link)
• Camilla Tøndel (2015). Har testet medisiner på 400 barn. (external link)
• Camilla Tøndel (2015). Kreft hos barn og betydning av klinisk utprøving hos barn. (external link)
• Camilla Tøndel (2022). Katrine (47) har meldt seg frivillig til å teste en ny, norsk vaksine. Håpet er at den skal beskytte lenger enn de man har hatt til nå. (external link)
• Camilla Tøndel (2022). Lovende resultater av mulig ny behandling av Fabry sykdom: – Stor praktisk betydning. (external link)
• Camilla Tøndel; Einar Svarstad (2013). Enzyme replacement in Fabry disease. (external link)
• Thomas Halvorsen; Camilla Tøndel (2014). Forskning på legemidler til barn må gjøres i Norge. (external link)

Conference abstract

• Robert Hopkin; F. Salomone; Derralynn A. Hughes et al. (2025). Évaluation de la relation entre les réactions liées à la perfusion et les anticorps antimédicament statut : résultats de 111 patients atteints de la maladie de Fabry traités par pegunigalsidase alfa. (external link)
• John Bernat; F. Salomone; Myrl Holida et al. (2025). Prolongation de l’intervalle entre les perfusions de pégunigalsidase alfa chez les patients atteints de la maladie de Fabry : résultats intermédiaires sur cinq ans de l’étude BRIGHT51 en cours. (external link)
• Frits Wijburg; Bernard Benichou; Daniel G Bichet et al. (2013). A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data. (external link)
• Behzad Najafian; Chester Whitley; Beth Thurberg et al. (2013). Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). (external link)
• Behzad Najafian; Emily Glynn; Einar Svarstad et al. (2012). Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. (external link)
• Camilla Tøndel; Leif Bostad; Einar Svarstad (2010). RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (external link)
• Camilla Tøndel; Anne Kjørsvik Bertelsen; Leif Bostad et al. (2009). Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. (external link)
• Camilla Tøndel; Uma Ramaswami; Kristin Moberg Aakre et al. (2009). Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate?. (external link)
• Camilla Tøndel; Leif Bostad; Liv Marie Lægreid et al. (2008). Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. (external link)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2013). GLOMERULAR FILTRATION RATE (GFR) MEASURED BY IOHEXOL CLEARANCE IN CHILDREN; A COMPARISON BETWEEN VENOUS SAMPLES AND DRIED BLOOD SPOTS. (external link)

Study protocol

• Bjørn Blomberg; Nikolai Norevik Myklebust; Oddvar Oppegaard et al. (2025). Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial | Trials | Full Text. (external link)

Conference lecture

• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). Low infection and seroconversion rates in frontline healthcare workers during the peak of the Coronavirus disease 2019 pandemic in Bergen, Norway. (external link)
• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). SARS-COV-2-Specific neutralising antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (external link)
• Amit Bansal; Mai Chi Trieu; Anders Madsen et al. (2020). Antibody responses to SARS-CoV-2 virus in Norwegian health-care workers: an observational prospective cohort study. (external link)
• Kristin Greve Isdahl Mohn; Rebecca Jane Cox; Fan Zhou et al. (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.. (external link)
• Olav H. Haugen; Camilla Tøndel; Einar Svarstad (2009). Corneal changes in Fabry's disease. (external link)
• Philipp Strauss; Øystein Solberg Eikrem; Camilla Tøndel et al. (2019). Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy. (external link)
• Camilla Tøndel; Idunn Riisnes; Sabine Leh et al. (2021). Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age. (external link)
• Camilla Tøndel; Leif Bostad; Einar Svarstad (2010). 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (external link)
• Camilla Tøndel; Einar Svarstad (2013). Podocytes: Therapeutic Target in Fabry Disease?. (external link)

Letter to the editor

• Bjørn Steinar Demma Lillås; Camilla Tøndel; Toralf Melsom et al. (2023). Response to Birth Weight and Renal Functional Reserve in Adults. (external link)
• Sigrid Bratlie; Muath K Alsheikh; Trygve Brautaset et al. (2023). Mer faglighet fra naturbevegelsen, takk. (external link)
• Anne Kjørsvik Bertelsen; Camilla Tøndel; Jørgen Gitlesen Krohn et al. (2013). Small fibre neuropathy in Fabry disease. (external link)
• Gunnar Houge; Camilla Tøndel; Øyvind Kaarbøe et al. (2011). Fabry or not Fabry – a question of ascertainment. (external link)

Academic literature review

• Camilla Tøndel; Beth L. Thurberg; Pronabesh DasMahapatra et al. (2022). Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. (external link)
• Allesandro Burlina; Eva Brand; Derralynn A. Hughes et al. (2023). An expert consensus on the recommendations for the use of biomarkers in Fabry disease. (external link)
• Christoph Wanner; Michael Arad; Ralf Baron et al. (2018). European expert consensus statement on therapeutic goals in Fabry disease. (external link)

Conference poster

• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2015). Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype. (external link)
• Robert Hopkin; Derralynn A. Hughes; John Bernat et al. (2025). Evaluating the relationship between infusion-related reactions and anti-drug antibody status: Results from 111 patients with Fabry disease treated with pegunigalsidase alfa. (external link)
• Rannveig Skrunes; Camilla Tøndel; Kristin Kampevold Larsen et al. (2015). LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY. (external link)
• Rannveig Skrunes; Einar Svarstad; Kristin Kampevold Larsen et al. (2015). DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS. (external link)
• John Bernat; Myrl Holida; Stephen Waldek et al. (2025). Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study. (external link)
• Aleš Linhart; Kathy Nicholls; Michael West et al. (2019). Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results. (external link)
• Rannveig Skrunes; Kristin Kampevold Larsen; Sabine Maria Leh et al. (2015). FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY. (external link)
• Eric Wallace; Ozlem Goker-Alpan; Myrl Holida et al. (2023). First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study. (external link)
• David Smerkous; Michael Mauer; Camilla Tøndel et al. (2023). Development of an online cloud-based tool for automatic measurement of foot process width (FPW) using deep learning (DL): Applications in assessment of podocyte injury in Fabry disease (FD). (external link)
• John Bernat; Myrl Holida; Nicola Longo et al. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. (external link)
• Camilla Tøndel; Eric Wallace; Rossana Rocco et al. (2022). Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa. (external link)
• Camilla Tøndel; Aleš Linhart; Gabriela Dostalova et al. (2020). Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study. (external link)
• David G Warnock; Eric Wallace; Raphael Schiffman et al. (2019). Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study. (external link)
• Myrl Holida; John Bernat; Nicola Longo et al. (2019). Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study. (external link)
• Behzad Najafian; Kathleen Nicholls; Michael L West et al. (2023). The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD). (external link)
• Øystein Solberg Eikrem; Nicolas Delaleu; Philipp Strauss et al. (2020). Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2019). Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss. (external link)
• John S Bradley; Natalia Makieieva; Camilla Tøndel et al. (2021). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-dose Clinical Trial. (external link)
• Nori JL Smeets; E Teunissen; E Teesselink et al. (2020). Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study. (external link)
• Camilla Tøndel; Kristin M. Aakre; Atle Brun et al. (2008). Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD. (external link)
• Camilla Tøndel; Bjørn Egil Vikse; Bjarne Magnus Iversen et al. (2008). Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis. (external link)
• David G Warnock; Ozlem Goker-Alpan; John Bernat et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (external link)
• Cathrin Lytomt Salvador; Per Tryggve Kjelland Flemmen; Berit Woldseth et al. (2023). Reduced renal function and other factors influence the measured level of glycosaminoglycans (GAGs) and could lead to diagnostic misinterpretation. (external link)
• Fu-Pang Chang; Michael Mauer; Alexey Sokolovskiy et al. (2016). Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2016). Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease. (external link)
• Aleš Linhart; Kathy Nicholls; Michael West et al. (2019). Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa. (external link)
• Einar Svarstad; Rannveig Skrunes; Sabine Maria Leh et al. (2017). Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease. (external link)
• Myrl Holida; John Bernat; Nicola Longo et al. (2019). New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study. (external link)
• Camilla Tøndel; Antonio Pisani; John A. Bernat et al. (2024). Cross-Sectional Analysis of Organ Involvement and Biomarker Levels in Patients With and Without Antidrug Antibodies to Enzyme Replacement Therapies for Fabry Disease. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2017). Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients. (external link)
• Uma Ramaswami; Frits Wijburg; Daniel G Bichet et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells. (external link)
• John Kopsidas; Sanne Hofstraat; Jon Salmanton-García et al. (2022). Capacity mapping and building for pediatric vaccine trials across Europe with VACCELERATE’s harmonized assessment tool. (external link)
• Uma Ramaswami; Frits Wijburg; Daniel G Bichet et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. (external link)
• Fabian Braun; Ahmed Abed; Mathias Woidy et al. (2021). Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy. (external link)
• Behzad Najafian; Camilla Tøndel; Einar Svarstad et al. (2018). Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease. (external link)
• Camilla Tøndel; Einar Svarstad; Leif Bostad (2009). Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy. (external link)
• John Bernat; Derralynn A. Hughes; Aleš Linhart et al. (2024). Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. (external link)
• Derralynn A. Hughes; John Bernat; Aleš Linhart et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens. (external link)
• Ankit Mehta; Eric Wallace; Aleš Linhart et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy. (external link)
• Myrl Holida; John Bernat; Nicola Longo et al. (2022). Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Results from the phase 3, open-label, BRIGHT study. (external link)
• Camilla Tøndel; Takahiro Kanai; Kristin Kampevold Larsen et al. (2014). Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters. (external link)
• Linda van der Tol; L Vogt; S Florquin et al. (2014). Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease. (external link)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2017). Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times. (external link)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Bjørn Egil Vikse (2020). Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age. (external link)
• Behzad Najafian; Aurelio Silvestroni; Alexey Sokolovskiy et al. (2022). Globotriaosylceramide (GL3) accumulation in Fabry podocytes in female patients is progressive with age and associated with podocyte loss and proteinuria. (external link)
• Einar Svarstad; Rannveig Skrunes; Einar Skulstad Davidsen et al. (2019). Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms. (external link)
• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2013). Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?. (external link)
• Camilla Tøndel; David G Warnock; Ozlem Goker-Alpan et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (external link)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Anna Gjerde et al. (2019). Measurement of renal functional response using iohexol clearance. (external link)
• Camilla Tøndel; AK Bertelsen; Leif Bostad et al. (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively. (external link)
• Cathrin Lytomt Salvador; Alexander D. Rowe; Anna Kristina Bjerre et al. (2016). Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine. (external link)
• Behzad Najafian; Michael Mauer; Einar Svarstad et al. (2014). Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr). (external link)
• Camilla Tøndel; Kristin Kampevold Larsen; Rannveig Skrunes et al. (2014). Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients. (external link)
• Hjørdis Thorsteinsdottir; Cathrin Lytomt Salvador; Camilla Tøndel et al. (2016). GDF-15 in plasma and urine as a marker of kidney function in children. (external link)
• Aleš Linhart; Gabriela Dostalova; Kathleen Nicholls et al. (2020). Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study. (external link)
• Rannveig Skrunes; Kristin Kampevold Larsen; Einar Svarstad et al. (2014). Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT). (external link)
• Cathrin Lytomt Salvador; Camilla Tøndel; Lars Mørkrid et al. (2013). Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots. (external link)
• Øystein Solberg Eikrem; Philipp Strauss; Miroslav Sekulic et al. (2018). Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy. (external link)
• Christoph Wanner; PM Elliot; V Formin et al. (2018). KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE. (external link)
• Camilla Tøndel; Cathrin Lytomt Salvador; Karl Ove Hufthammer et al. (2018). IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. (external link)
• Thea Tislevoll Eide; Atle Brun; Damien Brackman et al. (2018). SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION. (external link)

Doctoral thesis (PhD)

• Camilla Tøndel (2013). Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurements. (external link)
• Bjørn Steinar Demma Lillås; Camilla Tøndel; Bjørn Egil Vikse et al. (2024). Impact of birth weight on kidney health in middle-aged adults : Results from the Haugesund Low Birth Weight Study. (external link)
• Cathrin Lytomt Salvador; Lars Mørkrid; Stein Bergan et al. (2020). Estimation and measurement of glomerular filtration rate in children. (external link)
• Rannveig Skrunes; Camilla Tøndel (2017). Hereditary renal disease in the Norwegian population, with a focus on Fabry disease. (external link)
• Philipp Strauss; Øystein Solberg Eikrem; Hans Peter Marti et al. (2023). From archival tissues to systems biology: Using transcriptomics to investigate the progression of kidney disease. (external link)

Media feature article

• Sigrid Bratlie; Camilla Tøndel; Muath K Alsheikh et al. (2023). GMO-regler må ikke få stoppe utviklingen av avanserte terapier. (external link)
• Espen Gamlund; Muath K Alsheikh; Sigrid Bratlie et al. (2023). Uetisk å la være å satse på genteknologi. (external link)
• Sigrid Bratlie; Arne Holst-Jensen; Muath K Alsheikh et al. (2023). På tide å åpne for genteknologi i norsk matproduksjon. (external link)

Research report

• Anna Wargelius; Muath K Alsheikh; Espen Gamlund et al. (2023). Genteknologi i en bærekraftig fremtid. (external link)

Radio or TV participation

• Camilla Tøndel (2015). Liv og død-serien; Legemiddelutprøving hos barn. (external link)

Journal corrigendum

• Camilla Tøndel; Bjørn Johan Bolann; Cathrin Lytomt Salvador et al. (2016). Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). (external link)

See a complete overview of publications in NVA.

Filter - Nasjonalt vitenarkiv

PubMed

ResearchGate